Literature DB >> 9218619

Increased susceptibility to endotoxin shock in complement C3- and C4-deficient mice is corrected by C1 inhibitor replacement.

M B Fischer1, A P Prodeus, A Nicholson-Weller, M Ma, J Murrow, R R Reid, H B Warren, A L Lage, F D Moore, F S Rosen, M C Carroll.   

Abstract

Endotoxin shock is a life-threatening syndrome associated with a Gram-negative infection and mediated by a systemic inflammatory response. As a major effector of inflammation, the complement system has been implicated in both the pathogenesis and the protection from endotoxin shock. To clarify the role of complement in endotoxin shock, we have used mice totally deficient in either complement component C3 or C4. We found that both the C3- and C4-deficient mice were significantly more sensitive to endotoxin than wild-type controls. The endotoxin-challenged complement-deficient mice failed to clear endotoxin efficiently from the circulation and this led to excess consumption of C1 inhibitor protein (C1 INH), a major regulator of both complement and the contact system of blood coagulation. Replacement of C1 INH rescued the endotoxin-challenged complement-deficient mice from shock and death. These findings suggest a novel therapy for treatment of endotoxemia with C1 INH protein.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218619

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

Review 1.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

Review 2.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

3.  Functions of the complement components C3 and C5 during sepsis.

Authors:  Michael A Flierl; Daniel Rittirsch; Brian A Nadeau; Danielle E Day; Firas S Zetoune; J Vidya Sarma; Markus S Huber-Lang; Peter A Ward
Journal:  FASEB J       Date:  2008-06-27       Impact factor: 5.191

4.  The effect of human complement C3 protein applied at different times in treatment of polymicrobial sepsis.

Authors:  Yujie Yuan; Jianan Ren; Guosheng Gu; Shougen Cao; Jieshou Li
Journal:  Inflamm Res       Date:  2012-02-16       Impact factor: 4.575

5.  Complement-mediated lipopolysaccharide release and outer membrane damage in Escherichia coli J5: requirement for C9.

Authors:  A M O'Hara; A P Moran; R Würzner; A Orren
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

Review 6.  Endotoxin elimination in sepsis: physiology and therapeutic application.

Authors:  Klaus Buttenschoen; Peter Radermacher; Hendrik Bracht
Journal:  Langenbecks Arch Surg       Date:  2010-06-27       Impact factor: 3.445

7.  Mechanisms of enhanced lung injury during sepsis.

Authors:  B J Czermak; M Breckwoldt; Z B Ravage; M Huber-Lang; H Schmal; N M Bless; H P Friedl; P A Ward
Journal:  Am J Pathol       Date:  1999-04       Impact factor: 4.307

Review 8.  C1 inhibitor: molecular and clinical aspects.

Authors:  Marco Cicardi; Lorenza Zingale; Andrea Zanichelli; Emanuela Pappalardo; Benedetta Cicardi
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

Review 9.  Targeting of G-protein coupled receptors in sepsis.

Authors:  Abdul Rehman; Noor Ul-Ain Baloch; John P Morrow; Pál Pacher; György Haskó
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

10.  Acute lung injury induced by lipopolysaccharide is independent of complement activation.

Authors:  Daniel Rittirsch; Michael A Flierl; Danielle E Day; Brian A Nadeau; Stephanie R McGuire; Laszlo M Hoesel; Kyros Ipaktchi; Firas S Zetoune; J Vidya Sarma; Lin Leng; Markus S Huber-Lang; Thomas A Neff; Richard Bucala; Peter A Ward
Journal:  J Immunol       Date:  2008-06-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.